Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis.
Koichi MiyataEmelia V BaintoXiaoying SunSonia JainKirsten B DummerJane C BurnsAdriana H TremouletPublished in: Archives of disease in childhood (2023)
Primary adjunctive high-dose 10 mg/kg infliximab treatment was associated with a greater likelihood of CAA regression in patients with CAA at the time of diagnosis.